Single Arm,open Label,phase I Clinical Study of Venetoclax Combined with CACAG Regimen in the Treatment of Newly Diagnosed Acute Myeloid Leukemia

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 04 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Azacitidine (Primary) ; Tucidinostat (Primary) ; Venetoclax (Primary) ; Granulocyte colony stimulating factor stimulants
Indications Acute myeloid leukaemia
Focus Therapeutic Use

10 Dec 2024 Results(Between Junrary 1, 2020, and August 1, 2024, n=32) studying Chidamide in Combination with Dcag and Venetoclax in Acute Myeloid Leukemia , presented at the 66th American Society of Hematology Annual Meeting and Exposition
27 Sep 2024 Status changed from recruiting to completed.
15 Jun 2023 Results (n=13) assessing safety and efficacy of the therapeutic safety and efficacy of VAC for newly diagnosed (ND) AML-M5 patients presented at the 28th Congress of the European Haematology Association

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com